ArticleMolecular medicine reports2021
miR‑654‑3p suppresses cell viability and promotes apoptosis by targeting RASAL2 in non‑small‑cell lung cancer.
Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Mechanism underlying the role of the circRNA OMA1/miR-654-3p/RAF1 axis in children with inflammatory bowel disease.Cytotechnology · 2025Article
- Circular RNAs and cervical cancer: friends or foes? A landscape on circRNA-mediated regulation of key signaling pathways involved in the onset and progression of HPV-related cervical neoplasms.Cell communication and signaling : CCS · 2024Review
- Article
- Non-coding RNAs and exosomal non-coding RNAs in lung cancer: insights into their functions.Frontiers in cell and developmental biology · 2024Review
- Circ_0084188 promotes colorectal cancer progression by sponging miR-654-3p and regulating kruppel-like factor 12.The Kaohsiung journal of medical sciences · 2023Article
- Circ_0110498 facilitates the cisplatin resistance of non-small cell lung cancer by mediating the miR-1287-5p/RBBP4 axis.Thoracic cancer · 2023Article
- MicroRNAs as Quality Assessment Tool in Stored Packed Red Blood Cell in Blood Banks.Journal of blood medicine · 2023Review
- miRNome of Child A hepatocellular carcinoma in Egyptian patients.Frontiers in oncology · 2023Article
- Hypoxia-induced circRNF13 promotes the progression and glycolysis of pancreatic cancer.Experimental & molecular medicine · 2022Article
- Comprehensive Analysis of hsa-miR-654-5p's Tumor-Suppressing Functions.International journal of molecular sciences · 2022Article
- RASAL2 regulates the cell cycle and cyclin D1 expression through PI3K/AKT signalling in prostate tumorigenesis.Cell death discovery · 2022Article
- Article
- MiR-654-3p Constrains Proliferation, Invasion, and Migration of Sinonasal Squamous Cell CarcinomaFrontiers in genetics · 2021Article
- The Impact of lncRNAs and miRNAs on Apoptosis in Lung Cancer.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non‑small‑cell lung cancer (NSCLC) accounts for 80% of lung cancer cases, and is the leading cause of cancer‑associated mortality worldwide. The present study aimed to investigate the roles of microRNA (miR)‑654‑3p in NSCLC. The expression levels of miR‑654‑3p and its target ras protein activator like 2 (RASAL2) mRNA were determined by reverse transcription‑quantitative polymerase chain reaction; protein expression was analyzed by western blotting. Plasmids expressing miR‑654‑3p mimics were constructed and transfected into A549 cells. In addition, the viability and apoptotic rate of cells were analyzed by an MTT assay and flow cytometry, respectively. A luciferase reporter assay was performed to verify whether RASAL2 is a target of miR‑654‑3p. Downregulated miR‑654‑3p and upregulated RASAL2 expression were observed in tumor tissues and cells. Cell viability was suppressed and the apoptotic rate was increased in the miR‑654‑3p mimics‑transfected cells compared with the control. Luciferase activity was decreased in the RASAL2‑3' untranslated region‑wild type group treated with miR‑654‑3p mimics. Furthermore, the present study revealed that overexpression of miR‑654‑3p could suppress the viability and induce the apoptosis of cells by targeting RASAL2 in NSCLC. The present findings may contribute to developments in the treatment of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.